Yes. What it means is that given the multi-well c

Yes. What it means is that given the multi-well capability of the N-Assay system they can put a series of different bacterial tests on the single plate or "panel" (as Dr. Faro stated) rather than a petri plate that is good for only testing for one thing at a time. So in neonatal, for example, a woman can be tested for multiple kinds of bacterial infections. Dr. Faro indicated that a woman's vagina contains as many as 30 forms of bacteria and that the majority of them were pathogenic so having a multi-well panel means that the NanoLogix technology can be used to detect as well as eliminate possible infectious situations.

This expanded and simultaneous diagnostic capability opens the methodology up to multiple uses. The same can be said for the sepsis panel they are developing about which Dr. Faro spoke. Sepsis is incredibly serious and has various bacteriological causes so the wider the range of very fast and very accurate tests that can be done to identify and eliminate the better off the patient is. All in all the potential is incredible and my sense is that with the specificity of Dr. Faro's presentation that good things are getting close for patients, investors and NanoLogix.